FDA Grants Approval for Doxepin Hydrochloride ANDA213919 by Sun Pharma
The FDA has granted approval for ANDA213919, a generic version of Doxepin Hydrochloride submitted by Sun Pharma.
Company
Sun Pharma
Asset
Signal assessment
Signal strength
high
Confidence level
moderate
Why it matters
The FDA's approval of Sun Pharma's generic Doxepin Hydrochloride presents a significant shift in the competitive landscape for this therapeutic area. Portfolio teams must evaluate the implications for pricing and market share of existing branded products to strategize effectively.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor market entry timing and pricing strategies from Sun Pharma and competitors.
Related companies & assets
Companies
Sources & Humanexa intelligence
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.